Treatment Innovations
Innovations in cancer treatment are transforming patient care by introducing more precise, effective, and less invasive therapies. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has revolutionized cancer care by harnessing the immune system to target and destroy cancer cells.
New genetic code may be the key in understanding origins of ovarian cancer, new treatment options
ICHMOND, Va. (WRIC) — A group of scientists at Virginia Commonwealth University (VCU) may have the key to discovering cancer’s origins within the body, as well as insights into new treatment strategies for ovarian cancer.
Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients
Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival rates compared to those who do not receive the treatment.
Root cause of pancreatic cancer and new treatment
Pancreatic cancer is one of the deadliest forms of cancer. A specific type called pancreatic ductal adenocarcinoma, or PDAC, is especially aggressive. Right now, there are no truly effective treatments for this kind of cancer. Sadly, only about 8 out of every 100 people diagnosed with PDAC live longer than five years.
Scientists finds new treatment for lung cancer
Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking.
The unseen team of medical detectives at Northwestern Medicine using advanced techniques for cancer detection, treatment
CHICAGO (WGN) — While machines can scan and surgeons cut, it takes a special kind of doctor to determine the presence of cancer in a patient.
A powerful drug combo may treat pancreatic cancer
Pancreatic cancer is one of the deadliest cancers in the world. Only about 13 out of every 100 people with this disease survive for five years after being diagnosed.
Breast cancer drug Supinoxin shows potential for small-cell lung cancer in new tests
Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC).
The Targeted Pulse: Discover the FDAÕs Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.
China’s National Medical Products Administration (NMPA) Approves VYLOYª (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
OKYO, Jan. 5, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that China’s National Medical Products Administration (NMPA) has approved VYLOYª (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.
China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
OKYO, Jan. 5, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that China’s National Medical Products Administration (NMPA) has approved VYLOY™ (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.
Unique Stanford Medicine-designed AI predicts cancer prognoses, responses to treatment
A new artificial intelligence tool developed at Stanford Medicine combines data from medical images with text to predict cancer prognoses and treatment responses.
CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
SHANGHAI, March 2, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel (“satri-cel”, CT041) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who have failed at least two prior lines of therapy.
Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer
“I think the combination of a longer time of connectivity [between tislelizumab and] the receptor [and] the fact that [this agent] avoids the other macrophages…could have been partly responsible for the efficacy that we saw.”
FDA Grants Breakthrough Status to Endometrial Cancer Assay
The OncoSignature multiplex immunofluorescence assay received breakthrough device designation from the FDA for identifying patients with endometrial cancer who may benefit from ACR-368 (prexasertib) treatment.
Treatment advances across the cervical cancer spectrum – Nature Reviews Clinical Oncology
In this Review, the authors discuss key clinical trials and therapeutic advances that have informed the current treatment landscape for cervical cancers of all stages, including refinement of surgical management approaches, the establishment of chemoradiotherapy, and the integration of anti-angiogenic agents, immune-checkpoint inhibitors and antibody–drug conjugates.
3News exclusive: Breakthrough radiation therapy at University Hospitals cuts treatment time from weeks to days
A revolutionary advancement in cancer treatment at UH Seidman Cancer Center is dramatically reducing the time patients spend receiving radiation therapy.
How to prime tumors to be defeated by cancer immunotherapy
Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint inhibitors, to work.
This AI is creating cancer-killing molecules
The hunt for cancer-combatting antibodies normally relies upon human lab scientists combing through vast amounts of data. LabGenius’ automated AI robotic system has disrupted that process.
Cheap diabetes drug taken by millions of Britons could protect against deadly cancer
A diabetes drug which costs just 35p per pill could help prevent an aggressive form of blood cancer, according to University of Cambridge researchers.
Common antiparasitic drug shows promise in halting growth of aggressive skin cancer
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers
Medical cannabis shows potential to fight cancer, largest-ever study finds
Analysis aims to solidify agreement on cannabis’s potential as a cancer treatment, lead author of research says
Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery
Pancreatic cysts are fluid-filled sacs that can form in the pancreas.
How a common diabetes drug may help the immune system fight cancer
Metformin is best known as a reliable and affordable medication for managing type 2 diabetes.
